中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 7
Jul.  2017

Value of combined detection of AFP, CA19-9, and CEA in early diagnosis of primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2017.07.017
  • Received Date: 2016-12-01
  • Published Date: 2017-07-20
  • Objective To investigate the value of combined measurement of alpha-fetoprotein (AFP) , carbohydrate antigen 19-9 (CA19-9) , and carcinoembryonic antigen (CEA) in the early diagnosis of primary liver cancer.Methods A total of 248 patients who visited the outpatient service or were hospitalized in The Second Hospital of Nanjing from October 2014 to December 2016 were enrolled and divided into primary liver cancer group with 88 patients and non-tumor liver disease group with 160 patients.A total of 130 healthy subjects who underwent physical examination were enrolled as normal control group.The Roche cobas e 411 analyzer was used to measure the serum levels of the tumor markers AFP, CA19-9, and CEA, and the sensitivities and specificities of these markers or a combination of them were analyzed.Beckman Coulter AU5800 was used to measure biochemical parameters for liver function, and Biotek ELX808 was used to measure hepatitis B virus markers and HCV antibody.The receiver operating characteristic (ROC) curve was used to analyze the results of measurements of serum AFP, CA19-9, and CEA alone or in combination in patients with primary liver cancer.A one-way analysis of variance was used for comparison of continuous data between multiple groups and the SNK-q test was used for further comparison between two groups;the t-test was used for comparison of continuous data between two groups.The chi-square test was used for comparison of categorical data between groups.The Spearman correlation analysis was also performed.Results In the primary liver cancer group and the non-tumor liver disease group, the patients with abnormal liver function had significantly higher levels of AFP and CA19-9 than those with normal liver function (primary liver cancer group:t=35.64 and 3.38, both P<0.05;non-tumor liver disease group:t=12.51 and 8.19, both P<0.05) .Among the patients with normal liver function, the primary liver cancer group had a significantly higher level of CEA than the non-tumor liver disease group and the normal control group (all P<0.05) .Among the patients with abnormal liver function, the primary liver cancer group had significantly higher levels of AFP, CA19-9, and CEA than the non-tumor liver disease group and the normal control group (all P<0.05) .The serum levels of AFP, CA19-9, and CEA increased with the increase in Child-Pugh class.Among the patients with abnormal liver function in the primary liver cancer group, Child-Pugh class B patients had significant increases in the levels of AFP, CA19-9, and CEA compared with Child-Pugh class A patients, and Child-Pugh class C patients had significant increases compared with Child-Pugh class B patients (all P<0.05) .Among the patients with abnormal liver function in the non-tumor liver disease group, Child-Pugh class B patients had significant increases in the levels of AFP and CA19-9 compared with Child-Pugh class A patients, and Child-Pugh class C patients had significant increases compared with Child-Pugh class B patients (all P<0.05) ;Child-Pugh class C patients had a significant increase in the level of CEA than Child-Pugh class A/B patients (P<0.05) .The primary liver cancer group had significantly higher positive rates of AFP, CA19-9, and CEA than the non-tumor liver disease group and the normal control group (all P<0.05) , and the positive rates of these tumor markers were significantly higher when measured in combination than when measured alone (all P<0.05) .In the primary liver cancer group, a combination of the three tumor markers had a sensitivity of 86.36% and a specificity of 92.35%, while AFP, CA19-9, and CEA measured alone had sensitivities of 71.59%, 52.27%, and 39.77%, respectively.In the patients with primary liver cancer, the areas under the ROC curve for serum AFP, CA19-9, CEA, and a combination of them were 0.776, 0.704, 0.681, and0.817, respectively.AFP was positively correlated with gamma-glutamyl transpeptidase in the primary liver cancer group (r=0.54, P=0.04) and was positively correlated with indirect bilirubin (IBil) in the normal control group (r=0.50, P=0.01) .In the primary liver cancer group, CA19-9 was positively correlated with alanine aminotransferase (ALT) , direct bilirubin (DBil) , IBil, total bilirubin (TBil) , and total bile acid (TBA) (r=0.58, 0.63, 0.61, 0.65, and 0.58, all P<0.05) , and in the non-tumor liver disease group, CA19-9 was positively correlated with ALT, alkaline phosphatase (ALP) , DBil, IBil, TBil, and TBA (r=0.51, 0.63, 0.66, 0.64, 0.70, and 0.59, all P<0.05) .Conclusion AFP can well reflect liver injury, but it may yield false-negative results in the diagnosis of primary liver cancer.A mild increase in CEA does not strongly indicate primary cancer.CA19-9 is easily influenced by the factors including ALP and bilirubin and has a high false-positive rate.Combined measurement of AFP, CA19-9, and CEA can improve the sensitivity of the diagnosis of primary liver cancer and is better than single measurement of AFP, CA19-9, or CEA.Therefore, it provides a strong basis for early diagnosis and treatment.

     

  • [1]ZHAO YS, ZHANG LN, LI HC, et al.Clinical significance of serum GP73, AFP, and CA199 test in the diagnosis of hepatic cancer[J].Chin J Gastroenterol Hepatol, 2013, 40 (1) :29-32. (in Chinese) 赵运胜, 张丽娜, 李洪臣, 等.血清GP73联合AFP和CA199检测在肝癌诊断中的临床意义[J].中国肿瘤临床, 2013, 40 (1) :29-32.
    [2]ZENG YL, MA QF, XIONG W, et al.Relationships between HBV-M patterns and liver function, HBV-DNA in patients with chronic HBV infection of different stages[J].Int J Lab Med, 2015, 36 (4) :433-435. (in Chinese) 曾雅莉, 马清峰, 熊微, 等.不同病期慢性HBV感染者肝功能、HBV-DNA与HBV-M模式的关系[J].国际检验医学杂志, 2015, 36 (4) :433-435.
    [3]RAIN AJ, CHAN DW.Cancer proteomics:serum diagnostics for tumor marker discovery[J].Ann N Y Acad Sci, 2004, 1022:286-294.
    [4]SI X, TAN GJ.Value of tumor markers carcinoembryonic antigen, alpha-fetoprotein, and carbohydrate antigen 199 in diagnosis of liver cancer[J].Jilin Med J, 2008, 29 (16) :1392-1393. (in Chinese) 司序, 谭桂菊.探讨肿瘤标志物CEA、AFP、CA199在肝癌诊断中的应用价值[J].吉林医学, 2008, 29 (16) :1392-1393.
    [5]TIAN MF, HAN B.The clinical value of the detections of CA199, CA125, CA153 and CEA in malignant tumors[J].J Clin Exp Med, 2010, 9 (7) :483-485. (in Chinese) 田满福, 韩波.检测CA199、CA125、CA153及CEA在肿瘤诊断中的意义[J].临床和实验医学杂志, 2010, 9 (7) :483-485.
    [6]ZHANG N, WANG YX, HU J, et al.Application of levels of serum CA199, C3, C4 and lipid metabolism in clinical diagnosis of pancreatic cancer[J].J Jilin Univ:Med Edit, 2016, 42 (2) :295-300. (in Chinese) 张宁, 王颖娴, 胡健, 等.血清CA199、C3、C4及脂类代谢水平在胰腺癌临床诊断中的应用[J].吉林大学学报, 2016, 42 (2) :295-300.
    [7]GUO HM.Value of measurement of serum CA199 levels for diagnosis of hepatocirrhosis and carcinoma of liver[J].J Radioimmunol, 2003, 16 (4) :207-208. (in Chinese) 郭红梅.血清CA199在肝硬化与肝癌诊断中的价值[J].放射免疫学杂志, 2003, 16 (4) :207-208.
    [8]HUANG HT, ZHANG XF.CA199 Clinical significance of carbohydrate antigen 199 in liver cirrhosis and liver cancer[J].J Clin Hepatol, 2006, 22 (5) :379-380. (in Chinese) 黄海涛, 张筱风.CA199在肝硬化和肝癌中的临床意义[J].临床肝胆病杂志, 2006, 22 (5) :379-380.
    [9]DONG JZ, DENG ZY, ZHANG F, et al.Diagnostic value of combined detection of AFP, CEA and CA199 in primary liver cancers[J].Med J Natl Defend Forces Northwest China, 2011, 32 (4) :276-277. (in Chinese) 董菊子, 邓芝云, 张峰, 等.AFP、CEA和CA199联合检测在原发性肝癌诊断中的应用[J].西北国防医学杂志, 2011, 32 (4) :276-277.
    [10]ZHU W, GE JL, ZHANG LQ, et al.Clinical value of combined determination of alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 199, and cancer antigen 125 in diagnosis of liver cancer and liver cirrhosis[J].Int J Lab Med, 2012, 33 (15) :1902-1904. (in Chinese) 朱薇, 葛君琍, 张利强, 等.AFP、CEA、CA199、CA-125联合检测对肝癌、肝硬化诊断的临床价值[J].国际检验医学杂志, 2012, 33 (15) :1902-1904.
    [11]MEI Y, PENG CJ, CHEN L, et al.Early detective value of serum CA199 levels for concomitant acute cholangitis in obstructive jaundice[J].Chin J Pract Surg, 2015, 35 (4) :445-447. (in Chinese) 梅永, 彭瓷军, 陈丽, 等.血清CA199早期预判梗阻性黄疸发生急性胆管炎临床价值研究[J].中国实用外科杂志, 2015, 35 (4) :445-447.
    [12]RUAN SL, BI J.Influence of liver function on the detection of common tumor markers[J].World Chin J Dig, 2008, 16 (24) :2780-2784. (in Chinese) 阮水良, 毕军.肝功能生化指标对常用肿瘤标志物检测的影响[J].世界华人消化杂志, 2008, 16 (24) :2780-2784.
    [13]XIN WJ, ZHAO WJ.Combined detection of GP73, AFP and CA-199 in the diagnosis of primary liver cancer[J].Mod Oncol, 2016, 24 (7) :1083-1084. (in Chinese) 辛文娟, 赵文静.GP73、AFP、CA-199联合检测在原发性肝癌诊断中的应用价值[J].现代肿瘤医学, 2016, 24 (7) :1083-1084.
    [14]ZHENG HL, ZHAO R, LI DP, et al.Utility of DCP and AFP in diagnosis of primary liver cancer[J].Chin J Gen Prac, 2016, 14 (1) :29-31. (in Chinese) 郑海伦, 赵睿, 李大鹏, 等.肿瘤标志物DCP和AFP在原发性肝癌中的诊断价值[J].中华全科医学, 2016, 14 (1) :29-31.
    [15]ASUM N, CHOWDHURY HUA, CHOWDHURY MR, et al.Correlation of serum alpha-fetoprotein (AFP) level with liver function parameters in hepatitis B virus (HBV) infected patients in Bangladeshi population[J].Int JBiosci, 2012, 2 (9) :13-19.
  • Relative Articles

    [1]Zhiyao SHI, Xiaofei FAN, Yu GAO, Shaojian REN, Shiyu WU, Xixing WANG. The distribution pattern of traditional Chinese medicine syndromes and influencing factors for primary liver cancer: An analysis of 415 cases[J]. Journal of Clinical Hepatology, 2025, 41(1): 84-91. doi: 10.12449/JCH250113
    [2]Bibi XUAN, Yonghong XU, Zhongcai DU, Yu LIU, Yuling YANG, Cheng BIAN. Influencing factors for low-level viremia in patients with chronic hepatitis B or hepatitis B liver cirrhosis and its association with the progression of liver inflammation and liver fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2252-2259. doi: 10.3969/j.issn.1001-5256.2022.10.011
    [3]Tao WANG, Fenghui LI, Jing LIANG, Huiling XIANG, Fang LIU, Hongmin LYU, Baoxin QIAN, Jiajun TIAN. Clinical effect of direct-acting antiviral agents in treatment of chronic hepatitis C patients with thrombocytopenia[J]. Journal of Clinical Hepatology, 2022, 38(1): 91-96. doi: 10.3969/j.issn.1001-5256.2022.01.014
    [4]Yuqing YANG, Jia SHANG, Chengzhen LU, Song YANG, Hongyu CHEN, Jiali PAN, Yifan HAN, Hongli XI, Qian KANG, Ning TAN, Xiaoyuan XU. Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2022, 38(5): 1059-1063. doi: 10.3969/j.issn.1001-5256.2022.05.016
    [5]Jia LIAN, Tao HAN, Huiling XIANG, Yankai YANG, Tinghong LI, Lei LIU, Baiguo XU, Lixia SUN, Fei WANG, Yanchao FU. Influencing factors of rebleeding after gastroscopy in patients with liver cirrhosis and esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2021, 37(9): 2092-2096. doi: 10.3969/j.issn.1001-5256.2021.09.018
    [6]Dongqing ZHANG, Ruidan ZHENG, Minghua LIN, Wenjun WU, Shenglong LIN, Xiangmei WANG, Huaxi MA, Qin LI, Hanhui YE, Haibing GAO. Influencing factors for the 90-day prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(10): 2316-2319. doi: 10.3969/j.issn.1001-5256.2021.10.011
    [7]Li YANG, Ke SHI, Fangyuan GAO, Chongping RAN, Jie HOU, Xianbo WANG. Influencing factors for chronic kidney disease in patients with hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1817-1821. doi: 10.3969/j.issn.1001-5256.2021.08.015
    [8]Chaoyun XIE, Ping ZHANG, Minkai WANG. Influencing factors for severe acute pancreatitis with sepsis[J]. Journal of Clinical Hepatology, 2021, 37(4): 877-881. doi: 10.3969/j.issn.1001-5256.2021.04.030
    [9]Huibin NING, Huiming JIN, Kuan LI, Zhen PENG, Wei LI, Jia SHANG. Influencing factors for abnormal renal function markers in chronic hepatitis B patients receiving long-term oral administration of entecavir/tenofovir disoproxil fumarate[J]. Journal of Clinical Hepatology, 2021, 37(8): 1798-1801. doi: 10.3969/j.issn.1001-5256.2021.08.011
    [10]Hou YiHui, Liu TengFei, Zhao XiaoQing, Zhang LiaoYun. Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 84-87. doi: 10.3969/j.issn.1001-5256.2020.01.019
    [11]Liang Jing, Zhang YaPing, Liu Fang, Xiang HuiLing, Lu: HongMin, Han Tao. Efficacy of direct-acting antiviral agents in treatment of chronic hepatitis C and its effect on liver stiffness and aspartate aminotransferase-to-platelet ratio index[J]. Journal of Clinical Hepatology, 2020, 36(6): 1263-1267. doi: 10.3969/j.issn.1001-5256.2020.06.015
    [12]LIU YuWei, JIN JingLan, REN TianYi, GAO XiuZhu, LI Jie, ZHU Qing, NIU JunQi. Effect of direct-acting antiviral on the recurrence hepatitis C virus-related hepatocellular carcinoma after curative treatment: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2714-2719. doi: 10.3969/j.issn.1001-5256.2020.12.015
    [13]Lin ShunWei, Zhou ShuDong, Gao YanHui, Li YuePing, Jia WeiDong, Liang YingFang, Yang Yi. Compliance with antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(3): 532-535. doi: 10.3969/j.issn.1001-5256.2020.03.012
    [14]You GuoQiong, Wang Li, Duan Meng, Zhu Peng. Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 187-190. doi: 10.3969/j.issn.1001-5256.2019.01.041
    [15]Xu Li, Zheng YueQi, Shi Zhen, Chen YiYun, Shao HuiJiang, Chen JianJie. Influencing factors for the prognosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1870-1873. doi: 10.3969/j.issn.1001-5256.2019.08.050
    [16]Zhao XiTai, Nie QingHe. Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1067-1074. doi: 10.3969/j.issn.1001-5256.2017.06.010
    [17]Rao HuiYing, Wei Lai. The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals[J]. Journal of Clinical Hepatology, 2017, 33(5): 820-824. doi: 10.3969/j.issn.1001-5256.2017.05.005
    [18]Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
    [19]Liu HongLing, Zhang Min, Zang Hong, Zhou Xia, Yao Hong, Gao YinJie, Zhou ShuangNan, Liu ZhenWen. Clinical efficacy of direct-acting antiviral agents in treatment of patients with hepatitis C recurrence after liver transplantation[J]. Journal of Clinical Hepatology, 2015, 31(12): 2039-2041. doi: 10.3969/j.issn.1001-5256.2015.12.012
    [20]Zhou YouQian, Yin FengMing, Feng JingHua. Regularity of relapse after antiviral treatment in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2012, 28(8): 609-611.
  • Cited by

    Periodical cited type(17)

    1. 李斌华,陈小勇,李雷. 加强门静脉高压症的临床管理,促进失代偿性肝硬化再代偿. 肝脏. 2025(02): 262-265 .
    2. 杨晶艳,刘丽萍,陈梅春,周双红. 慢性乙型肝炎患者服药依从性的影响因素分析. 健康研究. 2024(02): 167-171+176 .
    3. 李斌华,谢峰,闫雪华,陈小勇,李雷,王文青. 综合医院MDT模式下肝硬化门静脉高压症患者全病程管理的探讨. 临床医学研究与实践. 2024(36): 182-185 .
    4. 罗发燕,陈铁霞,罗平平,诸伟红. 慢性乙型肝炎患者服药依从性调查. 预防医学. 2023(11): 966-969+974 .
    5. 蔡冬梅,胡婷婷. 网络互动式健康教育对中青年乙型肝炎患者疾病认知及治疗依从性的影响. 中国医药导报. 2022(04): 166-169 .
    6. 吕卉. 慢性病毒性肝炎患者治疗依从性的相关影响因素分析. 当代护士(上旬刊). 2022(01): 58-60 .
    7. 宋如梅,魏芹,李晶,薛群. “3-PR”参与式健康教育对慢性乙肝患者疾病认知及健康行为的影响. 海军医学杂志. 2022(01): 109-112 .
    8. 王玉美,李雪,范琪琪,王爱敏. 青岛慢性乙型肝炎患者抗病毒治疗服药依从性现状及影响因素分析. 社区医学杂志. 2022(04): 228-232 .
    9. 邓娜娜,周美芳. "5个时刻法"用药宣教应用于慢性乙型肝炎抗病毒治疗中的效果. 国际护理学杂志. 2022(06): 1104-1107 .
    10. 沈璐,周翠梅,张静,薛继华,李惠萍. 慢性乙型肝炎患者抗病毒治疗知信行量表的编制及信效度检验. 中国健康教育. 2021(03): 217-221 .
    11. 李振洁. 延伸护理服务在慢性乙型肝炎患者院外护理中的应用. 河南医学研究. 2021(07): 1329-1331 .
    12. 杨玲. 影响慢性乙型肝炎患者服药依从性相关危险因素及其干预措施分析. 内蒙古医学杂志. 2021(07): 836-838 .
    13. 王蕾,王丹,李汝珂,李长安,赵巍峰. “五个时刻法”延续用药指导在慢性乙型肝炎长期抗病毒治疗中的应用价值. 新乡医学院学报. 2021(06): 526-530 .
    14. 钟丽梅,唐霏林,杨柳琴,陆艳珍,黄桂敏,黄艳. 慢性乙型肝炎患者抗病毒治疗期间自我停药状况及影响因素. 河北医药. 2021(17): 2614-2617 .
    15. 田晓英. 医护药一体化模式对慢性乙型肝炎病人用药依从性及负性情绪的影响. 全科护理. 2021(34): 4857-4859 .
    16. 林顺伟,周舒冬,郜艳晖,李粤平,贾卫东,梁颖芳,杨翌. 慢性乙型肝炎患者抗病毒治疗的依从性分析. 临床肝胆病杂志. 2020(03): 532-535 . 本站查看
    17. 王贵菊,鲁荣华. 1022例慢性乙型肝炎病毒感染者现状及影响因素. 中国卫生工程学. 2020(03): 336-338 .

    Other cited types(4)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (3967) PDF downloads(563) Cited by(21)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return